XRTX XORTX Therapeutics Inc. Stock Quote

XRTX [NASD]

Index	-	P/E	-	EPS (ttm)	-0.44	Insider Own	5.15%	Shs Outstand	12.37M	Perf Week	-10.26%
Market Cap	24.50M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	12.29M	Perf Month	-28.21%
Income	-1.70M	PEG	-	EPS next Q	-	Inst Own	8.16%	Short Float	0.16%	Perf Quarter	-6.67%
Sales	-	P/S	-	EPS this Y	13.00%	Inst Trans	-	Short Ratio	0.10	Perf Half Y	-48.72%
Book/sh	1.35	P/B	1.04	EPS next Y	-	ROA	-14.50%	Target Price	-	Perf Year	-13.21%
Cash/sh	1.08	P/C	1.30	EPS next 5Y	-	ROE	-34.30%	52W Range	0.96 - 8.19	Perf YTD	-31.71%
Dividend	-	P/FCF	-	EPS past 5Y	10.90%	ROI	-	52W High	-82.90%	Beta	0.36
Dividend %	-	Quick Ratio	28.80	Sales past 5Y	-	Gross Margin	-	52W Low	45.60%	ATR	0.19
Employees	-	Current Ratio	28.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	41.49	Volatility	6.03% 14.49%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.13	Prev Close	1.47
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	199.20K	Price	1.40
Recom	-	SMA20	-11.28%	SMA50	-14.94%	SMA200	-46.05%	Volume	25,333	Change	-4.76%

May-05-22 07:00AM	XORTX Opens an IND for XRx-008 Program for Autosomal Dominant Polycystic Kidney Disease GlobeNewswire +8.75%
May-03-22 07:00AM	XORTX Initiates Dosing of Human Subjects in the XRX-OXY-101 Clinical Trial GlobeNewswire +57.76%
Apr-20-22 07:00AM	XORTX Receives Small and Medium Enterprise Status for the European Union GlobeNewswire
Apr-12-22 07:00AM	XORTX Receives No Objection Letter from Health Canada GlobeNewswire
Apr-07-22 07:00AM	XORTX Announces Grant of US Patent GlobeNewswire
Mar-31-22 07:00AM	XORTX Files IND with US FDA GlobeNewswire
Mar-23-22 07:00AM	XORTX Files New PCT Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection GlobeNewswire +43.80%
Mar-14-22 07:00AM	XORTX Therapeutics Announces Submission of Clinical Trial Application to Conduct Bridging Pharmacokinetics Study GlobeNewswire
Jan-31-22 07:00AM	XORTX Provides Corporate Update GlobeNewswire
Jan-20-22 07:00AM	XORTX Announces Appointment of Chief Technology Officer GlobeNewswire
Jan-12-22 08:30AM	Nanalysis Announces the Closing of Acquisition of K'(Prime) Technologies Inc. PR Newswire -7.80%
08:30AM	Nanalysis Announces the Closing of Acquisition of K'(Prime) Technologies Inc. CNW Group
Jan-10-22 07:00AM	XORTX to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference GlobeNewswire
Dec-22-21 08:30AM	Nanalysis Establishes Scientific Advisory Board with Four World Renowned Scientists CNW Group
Dec-21-21 06:00PM	XORTX Reports Annual & Special Meeting Results GlobeNewswire
07:00AM	XORTX Therapeutics Announces Filing of Provision Patent for Polycystic Kidney Disease GlobeNewswire
Dec-10-21 07:01AM	XORTX Therapeutics Announces Publication of Mt. Sinai Study of Hospitalized COVID-19 Patients GlobeNewswire -6.38%
Dec-09-21 11:53AM	Companies Like XORTX Therapeutics (CVE:XRTX) Can Afford To Invest In Growth Simply Wall St.
09:30AM	TMX Group Equity Financing Statistics - November 2021 CNW Group
08:04AM	XORTX Announces Research Coverage Initiated by A.G.P./Alliance Global Partners GlobeNewswire
Dec-02-21 07:00AM	XORTX Therapeutics Appoints Altasciences as CRO for Clinical Study GlobeNewswire -6.31%
Nov-23-21 07:00AM	XORTX Therapeutics Announces Annual and Special Meeting of Shareholders GlobeNewswire -8.33%
Nov-15-21 08:00AM	Argus Research Initiates Equity Research Report Coverage on XORTX Therapeutics Inc. (Nasdaq: XRTX) PR Newswire +9.09%
Nov-09-21 07:00AM	XORTX Therapeutics Announces Partial Exercise of Over-Allotment Option Pursuant to US Public Offering GlobeNewswire -13.71%
Nov-05-21 08:11AM	IIROC Trading Resumption - XRTX CNW Group
Nov-04-21 02:49PM	XORTX Therapeutics Clarifies Halt of Trading in Canada and Timing for Commencement of Trading on TSX Venture Exchange GlobeNewswire
08:21AM	IIROC Trading Halt - XRX CNW Group
Nov-02-21 06:13PM	XORTX Therapeutics Receives Final Approval to List on the TSX Venture Exchange GlobeNewswire
Oct-15-21 05:38PM	XORTX Therapeutics Announces Closing of US$12 Million Public Offering GlobeNewswire -6.21%
Oct-14-21 05:30PM	XORTX Announces Results from Mount Sinais COVID-19 Clinical Study GlobeNewswire
07:00AM	XORTX to Present at the LD Micro Main Event GlobeNewswire

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, hypertension, insulin resistance, and diabetic nephropathy. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is headquartered in Vancouver, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience